CN109563088B - MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途 - Google Patents

MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途 Download PDF

Info

Publication number
CN109563088B
CN109563088B CN201780049835.8A CN201780049835A CN109563088B CN 109563088 B CN109563088 B CN 109563088B CN 201780049835 A CN201780049835 A CN 201780049835A CN 109563088 B CN109563088 B CN 109563088B
Authority
CN
China
Prior art keywords
cancer
disease
pi3k
mek
tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780049835.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109563088A (zh
Inventor
布莱恩·D·罗斯
马尔奇安·范·杜特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan Ann Arbor
Original Assignee
University of Michigan Ann Arbor
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan Ann Arbor filed Critical University of Michigan Ann Arbor
Publication of CN109563088A publication Critical patent/CN109563088A/zh
Application granted granted Critical
Publication of CN109563088B publication Critical patent/CN109563088B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
CN201780049835.8A 2016-07-06 2017-07-06 MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途 Active CN109563088B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662359001P 2016-07-06 2016-07-06
US62/359,001 2016-07-06
US201762454163P 2017-02-03 2017-02-03
US62/454,163 2017-02-03
PCT/US2017/040866 WO2018009638A1 (en) 2016-07-06 2017-07-06 MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME

Publications (2)

Publication Number Publication Date
CN109563088A CN109563088A (zh) 2019-04-02
CN109563088B true CN109563088B (zh) 2022-10-11

Family

ID=59363277

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780049835.8A Active CN109563088B (zh) 2016-07-06 2017-07-06 MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途

Country Status (8)

Country Link
US (1) US10919877B2 (https=)
EP (2) EP4086250B1 (https=)
JP (2) JP2019519593A (https=)
CN (1) CN109563088B (https=)
AU (2) AU2017291838B2 (https=)
CA (1) CA3029875C (https=)
ES (2) ES3002745T3 (https=)
WO (1) WO2018009638A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018316175B2 (en) 2017-08-11 2023-02-23 The Regents Of The University Of Michigan Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K3k/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds
CN112143700B (zh) * 2019-06-26 2024-07-19 上海细胞治疗集团股份有限公司 制备过表达外源基因的免疫效应细胞的方法
CN117396470A (zh) * 2021-04-09 2024-01-12 巴塞尔大学 作为pi3k的可逆和不可逆共价抑制剂的三嗪衍生物
EP4320115A1 (en) * 2021-04-09 2024-02-14 Universität Basel Triazine derivative as reversible and irreversible covalent inhibitors of pi3k
WO2023170107A1 (en) 2022-03-07 2023-09-14 Centre Hospitalier Universitaire Vaudois (Chuv) Pi3k/akt/mtor inhibitor for improving the cellular uptake of a radiopharmaceutical
JP2023180347A (ja) * 2022-06-09 2023-12-21 国立大学法人金沢大学 ハイブリッド型化合物又はその塩
WO2025072796A1 (en) * 2023-09-27 2025-04-03 Totus Medicines Inc. Pharmaceutical compositions and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155121A2 (en) * 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
CN103748099A (zh) * 2011-05-19 2014-04-23 西班牙国家癌症研究中心 作为蛋白激酶抑制剂的大环化合物
CN105283454A (zh) * 2013-04-12 2016-01-27 阿萨纳生物科技有限责任公司 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉
CN105358156A (zh) * 2013-03-13 2016-02-24 密执安大学评议会 双重mek/pi3k抑制剂和使用其的治疗方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA197701A (en) 1920-03-02 Mcgoldrick Timothy Arm cushion for crutches
CA85878A (en) 1903-08-19 1904-03-08 George W. Peyton Carpenter's gauge
US5608110A (en) 1993-06-15 1997-03-04 Bracco International B.V. Heteroatom-bearing ligands and metal complexes thereof
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
TW200505834A (en) 2003-03-18 2005-02-16 Sankyo Co Sulfamide derivative and the pharmaceutical composition thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AR059339A1 (es) 2006-02-09 2008-03-26 Chugai Pharmaceutical Co Ltd Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
DK2074122T5 (da) 2006-09-15 2014-03-17 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidin0n-forbindelser og anvendelse deraf som pi3 inhibitorer
US8569378B2 (en) 2007-07-20 2013-10-29 Toshiyuki Sakai p27 protein inducer
EP2276750A2 (en) 2008-03-27 2011-01-26 Auckland Uniservices Limited Substituted pyrimidines and triazines and their use in cancer therapy
EP2143819A1 (de) 2008-07-11 2010-01-13 Siemens Aktiengesellschaft Beschichtungsverfahren und Korrosionsschutzbeschichtung für Turbinen-Komponenten
SG174527A1 (en) 2009-03-27 2011-11-28 Pathway Therapeutics Inc Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
US20110166191A1 (en) 2010-01-07 2011-07-07 Shijun Zhang 3-(2-amino-ethyl)-5-(3-cyclohexyl-propylidene)-thiazolidine-2,4-dione and its derivatives as multiple signaling pathway inhibitors and for the treatment of cancer
GB201007227D0 (en) 2010-04-30 2010-06-16 Univ Basel Piperazinotriazines
KR101759762B1 (ko) * 2010-08-10 2017-07-19 아스텔라스세이야쿠 가부시키가이샤 헤테로환 화합물
EP2640367A2 (en) 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
WO2013071698A1 (zh) 2011-11-17 2013-05-23 山东轩竹医药科技有限公司 三环类PI3K和/或mTOR抑制剂
CN105130960B (zh) * 2015-07-31 2018-07-06 沈阳药科大学 1,3,5-三嗪类衍生物及其应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009155121A2 (en) * 2008-05-30 2009-12-23 Amgen Inc. Inhibitors of pi3 kinase
CN103748099A (zh) * 2011-05-19 2014-04-23 西班牙国家癌症研究中心 作为蛋白激酶抑制剂的大环化合物
CN105358156A (zh) * 2013-03-13 2016-02-24 密执安大学评议会 双重mek/pi3k抑制剂和使用其的治疗方法
CN105283454A (zh) * 2013-04-12 2016-01-27 阿萨纳生物科技有限责任公司 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Discovery of bifunctional oncogenic target inhibitors against allosteric mitogen-activated protein kinase (MEK1) and phosphatidylinositol 3-kinase (PI3K)";Marcian E. Van Dort，et al.;《Journal of medicinal chemistry》;20160304;第59卷(第6期);第2512-2623页 *
"Phospshoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors: Discovery and Structure Activity Relationships of a Series of Quinoline and Quinoxaline Derivatives";Nobuko Nishimura，et al.;《Journal of medicinal chemistry》;20110525;第54卷;第4735-4751页 *
Marcian E. Van Dort，et al.."Discovery of bifunctional oncogenic target inhibitors against allosteric mitogen-activated protein kinase (MEK1) and phosphatidylinositol 3-kinase (PI3K)".《Journal of medicinal chemistry》.2016,第59卷(第6期),第2512-2623页. *

Also Published As

Publication number Publication date
ES3002745T3 (en) 2025-03-07
EP4086250B1 (en) 2024-12-11
EP4086250A3 (en) 2023-03-22
JP7475062B2 (ja) 2024-04-26
JP2019519593A (ja) 2019-07-11
CA3029875A1 (en) 2018-01-11
CN109563088A (zh) 2019-04-02
CA3029875C (en) 2023-12-19
EP4086250C0 (en) 2024-12-11
JP2022019812A (ja) 2022-01-27
EP3481822A1 (en) 2019-05-15
AU2017291838B2 (en) 2021-01-28
AU2017291838A1 (en) 2019-01-17
US10919877B2 (en) 2021-02-16
AU2021202619A1 (en) 2021-05-27
WO2018009638A1 (en) 2018-01-11
EP4086250A2 (en) 2022-11-09
AU2021202619B2 (en) 2022-03-10
ES2922898T3 (es) 2022-09-21
EP3481822B1 (en) 2022-06-22
US20190224207A1 (en) 2019-07-25

Similar Documents

Publication Publication Date Title
CN109563088B (zh) MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途
JP6315848B2 (ja) Ｍｅｋ／ｐｉ３ｋ二重阻害剤および該阻害剤を使用する治療方法
TWI726362B (zh) Bcl-2抑制劑與利妥昔單抗和/或苯達莫司汀或Bcl-2抑制劑與CHOP聯合用藥的協同抗腫瘤作用
JP2009538317A (ja) 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ
KR20180132618A (ko) 아미노티아졸 화합물 및 이의 용도
CN105120868A (zh) 组合治疗
JP6155026B2 (ja) プロテインキナーゼ阻害のための新規化合物及びその治療的使用
BR112019022553A2 (pt) novo derivado de tetrahidronaftil ureia
CN109310650A (zh) 用于减少过表达c-myc的癌症中的c-myc的化合物
CN102438612B (zh) 腈衍生物及其药学用途与组合物
WO2020077361A1 (en) Compounds and methods of their use
CN106459011B (zh) 作为抗肿瘤化合物的σ-2受体配体药物缀合物、其合成方法及其用途
TW202021591A (zh) B細胞惡性腫瘤之治療
US9399644B2 (en) [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
TWI920088B (zh) Ｓｉｋ-３抑制劑及其用途
WO2025207686A2 (en) Small molecule modified boron containing compounds and methods of use thereof
CN121240859A (zh) 用于治疗健康状况的组合物和制备和使用小分子的方法
WO2015011008A1 (en) 7-azaindole derivatives as parp inhibitors
HK1194308B (en) Methods and use of bifunctional enzyme-building clamp-shaped molecules
HK1120406A (en) Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant